RecruitingPhase 2NCT04981509
Renal
Hereditary leiomyomatosis and renal cell cancer
5
studies recruiting now
as of 7 Sept 2026
12
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
29 Jul 2021
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00050752
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
RecruitingNCT00001238
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RecruitingNot applicableNCT04623502
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RecruitingNCT03749980
MyVHL: Patient Natural History Study
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Hereditary leiomyomatosis and renal cell cancer studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hereditary leiomyomatosis and renal cell cancer study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Hereditary leiomyomatosis and renal cell cancer
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (FH).
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).